Overview
Lobbying Costs
75,000€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
0.75 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Medtech & Pharma Platform (MPP)
EU Transparency Register
234427831877-10 First registered on 25 Jun 2018
Goals / Remit
The Medtech & Pharma Platform Association (MPP) is a cross-sectoral not-for-profit industry association focusing on combined products, i.e. products that combine aspects of drugs, devices, diagnostics and/or software to fulfil a medical purpose. Members are Medtech, Pharma and Software companies as well as organizations dedicated to enhancing synergies between the sectors.
Current and future innovative healthcare solutions increasingly rely on combined products developed by pharma- medtech and software companies. Collaboration between the sectors is therefore key to future innovations for patients and foster competitiveness on a global scale.
Since combined products are governed by very different regulatory regimes, which inevitably create regulatory uncertainties, the MPP offers expertise and seeks dialogue with relevant stakeholders to collaborate on a proportionate regulatory framework for combined products.
The association’s goals are
• Establish new cross-sectoral industry collaboration models to ensure and accelerate market access for safe and innovative treatment options in the field of combined products.
• Engage with relevant stakeholders and manage the interface between industry, policy makers, regulators and notified bodies to foster an open and transparent dialogue.
• Provide a platform for joint work on a balanced and proportionate regulatory and political framework for combined products that
o facilitates innovation for the European market, it’s industries and citizens
o strengthens public health through improved patients’ access to innovative products
o reduces time to market for drugs, devices and combinations thereof
o promotes free trade and IP principles
Medtech & Pharma Platform acts with a global mindset but initially focusses on European policy developments.Main EU files targeted
The Medtech & Pharma Platform Association was founded in 2017 and started its activities in 2018.
The Medtech & Pharma Platform monitors EU legislative, policy and regulatory developments relating to combined products.
Specifically, the Medtech & Pharma Platform follows:
• Medical Device Regulation EU 2017/745 & In vitro Diagnostic Regulation EU 2017/746
and their implementing and delegated acts as well as any related guidance document
• Medicinal Product Directive EU 2001/83
• Proposal for a Regulation on Health Technology Assessment
• General Data Protection Regulation EU 2016/679
• Clinical Trials Regulation EU 536/2014
• Policy initiatives, projects, events and publications from DG SANTE, DG GROW, DG CONNECT, DG RESEARCH
• EU Pharmaceutical Strategy - Timely patient access to affordable medicines
• New Industrial strategy for Europe
• European’s Digital Strategy
• Horizon 2020 / Horizon Europe
• Institutional agreement Switzerland-EUAddress
Head Office
Medtech & Pharma Platform
c/o SFL Regulatory Affairs & Scientific Communication GmbH
Basel 4002
SWITZERLAND -
People
Total lobbyists declared
2
Employment time Lobbyists 50% 1 25% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Within the cluster of 25% working time there are two persons which together work 25 %.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Trade and business associations
-
Networking
Affiliation
n.a.
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
75,000€
Other financial info
MPP is funded by membership contributions
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
Stakeholder engagement, projects:
The MPP engages with relevant stakeholders on a European level, offers expertise and seeks dialogue to collaborate on a proportionate regulatory framework for combined products.
MPP has two active working groups in place which develop comprehensive reflection papers and best-practice guides related to combined products:
• Working Group on Combined Products, focusing on co-packaged drug-device-combinations and single integral combination products
• Working Group on Connected Combined Products (device, drug, in-vitro diagnostic, digital applications), focusing on regulatory aspects of connected combined products
Publications:
White Paper on EU regulatory and policy framework for combined products; October 2018
Reflection paper on regulatory uncertainties for co-packaged and cross-labelled drug-device combinations under the new Medical Device Regulation, December 2019
Events:
MPP annual conference
• The annual MPP conference is the leading event in the sector of products and solutions that combine medtech and pharma components. The event is dedicated to enhancing partnership between the pharma and medtech industries.
The conference provides a forum to exchange knowledge, identify new challenges and opportunities, initiate collaborations and propose improvements to regulatory frameworks and policy, toward the goal of expediting patient access to innovative combined products
Trainings
The MPP association offers specialized, accredited training courses providing comprehensive and up-to-date insights on the latest regulatory and legislative developments related to combined products, medicinal products, medical devices, and invitro diagnosticsOther activities
MPP is acknowledged as Industry stakeholder for interaction with the European Medicines Agency (EMA)
- Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 15 Jun 2018 Location Brussels, Berl Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)
- Vytenis Andriukaitis (Commissioner)
Other Lobbyists - European Plastics Converters Association
- European Confederation of Pharmaceutical Entrepreneurs
- European Federation of Pharmaceutical Industries and Associations
- EuropaBio
- Association of the European Self-Care Industry
- MEDICINES FOR EUROPE
- MedTech Europe
- European Coordination Committee of the Radiological, Electromedical and healthcare IT Industry
- Plasma Protein Therapeutics Association Europe, international Association without lucrative purpose
- Meetings